B超引导下选择性神经根阻滞联合普瑞巴林治疗脑卒中后神经病理性疼痛38例疗效观察

Treatment of 38 cases of neuropathic pain after stroke by B ultrasound-selective nerve root block combined with pregabalin

目的:观察B超下选择性神经根阻滞联合普瑞巴林对脑卒中后神经病理性疼痛的治疗效果。方法:将76例脑卒中后神经病理性疼痛患者随机分为观察组(38例)和对照组(38例),两组患者均给予普瑞巴林治疗,观察组在此基础上实施B超下选择性神经根阻滞治疗,比较两组治疗总有效率,疼痛评分(VAS),睡眠质量评分(QS),神经系统功能恢复情况及不良反应。结果:观察组治疗总有效率为94.74%,对照组为71.05%,差异有统计学意义(P<0.05);两组治疗后VAS评分和QS评分均降低,且观察组评分降低更明显(P<0.05);观察组治疗后美国国立卫生院卒中量表评分(NHISS)和日常生活能力量表评分(ADL)分别为(13.01±1.34)、(57.19±9.84)分,明显好于对照组(P<0.05);观察组患者不良反应发生率为7.89%,低于对照组的21.05%(P<0.05)。结论:B超下选择性神经根阻滞联合普瑞巴林治疗脑卒中后神经病理性疼痛疗效显著,可有效缓解患者的疼痛程度,改善神经功能,降低不良反应的发生,具有重要的临床价值。

Objective:To observe the therapeutic effect of B-subacute selective nerve root block combined with pregabalin on post-stroke neuropathic pain.Methods:Sixty-seven patients with post-stroke neuropathic pain were randomly divided into observation group(38 cases)and control group(38 cases).Both groups were treated with pregabalin.The observation group was given B-Nerve root block treatment,the treatment of total effective rate,pain score(VAS),sleep quality score(QS),nervous system function recovery and adverse reactions were compared.Results:The total effective rate of the observation group was 94.74%,while that of the control group was 71.05%,the difference was statistically significant(P<0.05).The VAS score and QS score of the two groups were decreased after treatment,and the scores of the observation group decreased significantly(P<0.05).The scores of NHISS and ADL in observation group after treatment were(13.01±1.34)and(57.19±9.84),respectively,which were significantly better than those in control group(P<0.05).The incidence of adverse reactions in the observation group was7.89%,which was lower than 21.05% of the control group(P<0.05).Conclusion:B-suboptimal selective nerve root block combined with pregabalin is effective in treating post-stroke neuropathic pain.It can effectively relieve the patient's pain,improve neurological function and reduce the incidence of adverse reactions,and has important clinical value.